Zenas BioPharma secures up to $300M from Royalty Pharma for obexelimab royalty

Zenas BioPharma, Inc.

Royalty Pharma pays $75M upfront; additional $75M upon INDIGO trial success, $75M on FDA approval for IgG4-RD, $75M on FDA approval for SLE.
Royalty Pharma receives 5.5% royalty on worldwide net sales of obexelimab and certain other payments.
Zenas expects cash to fund operations through Q1 2027; topline Phase 3 INDIGO results expected year-end 2025.
Obexelimab is in Phase 3 for IgG4-RD, Phase 2 for RMS and SLE; potential U.S. launch in H1 2027 if approved.

item 1.01item 2.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.